Our ongoing Phase III luspatercept studies in later line low risk MDS and non-transfusion dependent beta-thalassemia, I expect it to be fully recruited during the second quarter, which represents an acceleration of six months versus original plan with an expected readout of top line results by mid 2018. In summary, we had a great start to the year for the Hematology and Oncology franchise and we are on track to deliver our 2017 guidance